VivoSeq
Respiratory

COPD Exacerbation

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

COPD Exacerbation is an early-stage landscape with 0 programs across 4 companies. The most active players are AstraZeneca, Boehringer Ingelheim, Lallemand Pharma AG.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalL

Lallemand Pharma AG

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed8 · 50%
Unknown status3 · 19%
Not yet recruiting3 · 19%
Withdrawn1 · 6%
Recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Atorvastatin Effect on Reduction of COPD Exacerbations
Recruiting·MMedical University of Bialystok·Phase 4·NCT04789057·460 enrolled
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Not yet recruiting·—·Phase 1·NCT07275359·45 enrolled
A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
Not yet recruiting·—·N/A·NCT06915688·188 enrolled
Dynamic Changes in Right Ventricle and Pulmonary Artery Coupling Among COPD Patients With Acute Exacerbation
Not yet recruiting·AAssiut University·N/A·NCT07694713·115 enrolled
Advanced Immunological Approach in COPD Exacerbation
Completed·LLallemand Pharma AG·Phase 4·NCT02417649·288 enrolled
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations
Completed·UUniversity of Chicago·Phase 1·NCT00116402·15 enrolled
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT01663987·79 enrolled
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
Completed·Novartis logoNovartis·Phase 3·NCT01782326·3,362 enrolled
Targeted Retreatment of COPD Exacerbations
Completed·IImperial College London·Phase 3·NCT02300220·144 enrolled
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT01662986·79 enrolled
Tezepelumab COPD Exacerbation Study
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT04039113·337 enrolled
Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations
Completed·—·Phase 4·NCT01865500·100 enrolled
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
Withdrawn·AstraZeneca logoAstraZeneca·Phase 4·NCT05970263
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation
Unknown status·UUniversity Hospital, Montpellier·Phase 3·NCT04234360·600 enrolled
The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation
Unknown status·—·Phase 3·NCT05769738·200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)